Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean urea c 10 and catus acid?
Displaying drugs 15576 - 15600 of 15745 in total

4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE

Experimental

(3R,4S)-1-[(4-AMINO-5H-PYRROLO[3,2-D]PYRIMIDIN-7-YL)METHYL]-4-[(METHYLSULFANYL)METHYL]PYRROLIDIN-3-OL

Experimental

Rimiterol

Experimental

4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine

Experimental

Verucerfont

Verucerfont has been used in trials studying the treatment of Congenital Adrenal Hyperplasia.
Investigational

A-98881

Experimental

ATX-201

ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Matched Description: … The Company determined that the program was not meeting their expected primary and exploratory objectives …

4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one

Experimental

NV-18

NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma...
Investigational
Matched Description: … almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and …

Sirna-027

Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. …

7-Deazaguanine

Experimental

(1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone

Experimental

(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(butylsulfanyl)methyl]pyrrolidin-3-ol

Experimental

4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine

Experimental

Fazadinium bromide

Experimental

(5S)-2-{[(1S)-1-(2-fluorophenyl)ethyl]amino}-5-methyl-5-(trifluoromethyl)-1,3-thiazol-4(5H)-one

Experimental

Fenoxazoline

Experimental

DAS869

Experimental

(3,4-Dihydroxy-Phenyl)-Triphenyl-Arsonium

Experimental

Immucillin-G

Experimental

4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL

Experimental

(5S)-2-{[(1S)-1-(4-Fluorophenyl)ethyl]amino}-5-(2-hydroxy-2-propanyl)-5-methyl-1,3-thiazol-4(5H)-one

Experimental

4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

Experimental

(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine

Experimental

MRX-I

MRX-I has been used in trials studying the treatment of Bacterial Infections.
Investigational
Displaying drugs 15576 - 15600 of 15745 in total